Vivos Inc (QB) (RDGL) Quote

Yep lot of people when you include 50000 posts from one poster lol what a fraud

Glad I made my big move during the last anticipatory run up.. This one seems to not be generating much steam.

He's a FUD"ster wannabe.  Not even good at it. Pretty sad 

Apparently a lot of people LMAO.

It is not a scam. RDGL is an amazing company.

As a loyal shareholder though, I am pissed off regarding the way they handle IsoPet. Someone once remarked "every time they mention IsoPet
the stock price drops". -
That is an accurate statement 90 percent of the time!!!!!!!!!!!!!!!!!!!!!!!!

Why??? To many discounts-- which can be attributed to two root factors.

1. Dishonest veterinarians milking all the freebies they can obtain.

2. Naive RDGL management that is incapable of cutting the freebie chord.

Translation -- mention a new clinic or conference= Stock price drops lower

The same group, including yourself, would say the same thing if MK was putting out several updates and PRs, calling it a pump. You're a joke.  Move along now 🤣

How is this scammy?  The Dr in charge would go immediately to jail as they have been clear on their intentions publicly, meaning, they blatantly burried their own grave already if this was a scam.  

The only people who still believe Vivos ""smells scammy"" are the stock scammers and the fake arseclowns who know nothing about trading.

Even with all the evidence, ie official FDA acknowledgement, proof of concept via Isopet and an ongoing clinical trial, we still get these planks spewing their garbage.

Volume seems to picking up a tad here.

RDGL AND ISOPET $12.50 soon IMO

See $2 next month.

Yes, like I said, 60% chance of success in my opinion... I think it's a pretty solid risk reward but will see. 

But yet you're still invested here. Seems odd.





$RDGL

seems the only ppl thinking this is a gem are the people that are long term investors. A lot of outsiders think this smells scammy... seems odd there is no hype/ no price increase going into major news events less than a few weeks away.

$6.

$5

No real change in the RSI and MFI data for the past 2 weeks but Accumulation has continued its modest upward trend.

What's the going rate these days......$0.05 per post!?!

You stock fraudsters are indeed truly pathetic.

But who's counting after 7 years here.

You must truly love yourself and not in a healthy way.

Yup

What's another 3 weeks after a few years?

That's what I love about you konshe.

Your optimism!!!!!!!!

Maybe RDGL should consider sharing it with the FDA?

False pretenses - LMAO

You have been for a very long time.

Good for you.

Check his and others history - it's been written many times.

Seriously?

I haven't been on this board for a long time, because I grew tired of reading this kind of post.

Are you fairly new here?

Been reading that kind of post for years.

I seriously hope it happens.

Haven't we bee standing on the doorstep for years now?

Haven't we been prepared to submit what could be the final sprint package that opens the gates to human trials for years now?

Let that sink in.

We have been, potentially weeks, years away form the FDA green lighting the use of RadioGel in human cancer patients.

It hasn't happened.

I hope it does!!!!!!!!!!!!!!!

Is the train in the station?

Or, 12 1/2 trading days (if we don't count the rest of today or July 14th.). July 3rd is early close and the market is closed on the 4th.

Another round of pathetic whinging........do better fraudster!

You post nothing but brainless absurdities.

My idiotic premise is still grossly absurd?

LMFAO

I would suggest you huddle with others but you already have - this board - and still don't have an intelligent talking post.

Pathetic

By July 14th:

https://x.com/RadioGel/status/1918328552455585815/photo/1

tic toc....tic toc....tic toc....BOOM!!

Just a maximum of 3 weeks until FDA submission!!

RDGL will break out 0.13 Today

You're welcome!

Don't forget to share it with friends and family and your favorite media sources.



$RDGL

Thank you sir,
Very informative, and why I’ve chose to ride high on RDGL! Time will tell…

I would expect so...if you listen to the interview he sounds open to anything to speed things up. A medical device is still a medication and quite often the medication is already well known, like Y90. So there is lots of data....the gist of the interview he states if there is already data from somewhere else on a study then they will use that data

Is this the same for Medical Devices?




$RDGK

AI Overview
The new FDA Commissioner, Dr. Marty Makary, has announced a new pilot program called the Commissioner's National Priority Voucher (CNPV) program. This program aims to significantly shorten the drug application review time, potentially reducing it to one to two months for certain drugs that align with the FDA's national priorities. These priorities include addressing health crises, delivering innovative cures, meeting unmet public health needs, and increasing domestic drug manufacturing.

Here's a breakdown of the key aspects:
CNPV Program:
The program awards vouchers to companies developing drugs that address the FDA's national priorities, allowing for expedited review.
Review Time:
Qualifying drugs could see their review time slashed from the typical 10-12 months to just one or two months.
National Priorities:
The program focuses on drugs that address critical health needs, such as a health crisis, deliver innovative cures, address unmet needs, or boost domestic drug manufacturing.
Split-Submission:
The program utilizes a split-submission approach, allowing companies to submit parts of the application, like chemistry, manufacturing, and controls (CMC) data, while clinical trials are still underway.
Voucher Characteristics:
The vouchers are non-transferable and have a two-year expiration date, according to the FDA.
AI Integration:
The FDA is also exploring the use of artificial intelligence, specifically a tool called ELSA, to assist with data curation and retrieval during the review process.
Operational Efficiency:
The program aims to leverage the time spent during clinical trials by allowing for early submission of certain application components.
Focus on Communication:
The program emphasizes enhanced communication and collaboration between drug developers and FDA reviewers.

The program is designed to be a pilot, with the potential for adjustments after the first year. It builds upon existing FDA programs like priority review and breakthrough therapy designation.

This is a very encouraging thought out post there’s not one thing that anyone could disagree with IMO but as it is we’re still ,and always will be at the mercy of the FDA .We’ll see.

I appreciate that.

We’re at a rare moment in time where the world needs to hear this story — not just investors, but anyone who believes in medical innovation, cancer breakthroughs, and the underdog winning.

Please share it anywhere and everywhere — Facebook, Twitter, family, friends, cancer support communities, investor groups. This isn’t just a ticker — it’s a mission. The more eyes we get on RadioGel, the more pressure builds behind the truth: RDGL is on the verge of something transformational.

Let’s not just watch history unfold — let’s help it happen.

Appreciate you watching from Baltimore. Let’s bring it home.


$RDGL

Wallnut, thanks for laying it out there for all to easily understand the magnitude of this moment in time. I would hope we can repost it every day until the next shoe drops. Watching intently from Baltimore.

I see that and I strongly suspect he's not the only one here posting under false pretenses.

Excellent post brother!! $RDGL long and strong!

Well written! Please post on the board, if possible 

Well written!!

The Tipping Point: RadioGel Is About to Change Everything.


To those watching from the sidelines, wondering if Vivos Inc. (RDGL) and its flagship cancer-fighting technology RadioGel® are worth the investment — let me make this crystal clear:

We are now standing on the doorstep of FDA IDE (Investigational Device Exemption) submission. After years of R&D, animal studies, dosimetry testing, safety validation, radiation delivery modeling, and navigating every regulatory hurdle the FDA has thrown their way, Vivos is preparing to submit what could be the final sprint package that opens the gates to human trials.

Let that sink in:
We are potentially weeks, not years, away from the FDA greenlighting the use of RadioGel in human cancer patients.


---

Why This Matters

RadioGel isn’t just another radiation therapy — it’s a precision-targeted injectable that delivers internal beta radiation directly into solid tumors using a hydrogel matrix. No systemic toxicity. No damage to surrounding healthy tissue. No side effects like you’d see with chemo or external beam radiation. It’s localized, lethal to the tumor, and safe for the patient.

This is the future of interstitial cancer therapy.

Once this treatment enters human trials under the IDE, Vivos isn’t just another speculative biotech — it becomes a first-in-class oncology device company with the ability to address cancers that current technologies cannot treat effectively.


---

For the Fence-Sitters

Yes, it’s been a long road. But biotech breakthroughs don’t happen overnight. What matters is that we’re here now, at the inflection point — when all the science, safety, and data align with regulatory readiness.

And let’s be honest — once that IDE is accepted, everything changes:

Institutional eyes come in

Licensing and partnership talks intensify

Market credibility skyrockets

Valuation? Re-rated overnight


Investors ask, “What’s the upside?” I say: what’s the value of a platform that can be used across multiple tumor types, both in humans and animals, and has already shown strong efficacy in preclinical models?

Add to that the IsoPet® veterinary division, already generating clinical interest and helping animals survive aggressive tumors — validating the core science behind the gel. It’s working.


---

The CEO’s Mission Is Personal

Let’s not forget: CEO Mike Korenko isn’t your typical executive padding a résumé. His goal is personal — he wants to see RadioGel save a child with brain cancer before his time is done. That’s the kind of leadership you cannot buy. That’s a mission you invest in.


---

Final Thought

You don’t get many chances in the market to be early to a disruptive cancer therapy backed by real science, peer-reviewed data, animal success, and now on the verge of human trials.

The train hasn’t left the station yet — but the whistle is blowing.

I’m not just holding. I’m invested in a medical revolution.

– Long and strong on $RDGL

The mission to Make America Healthy Again (MAHA) includes MABA — Make American Biotech Accelerate.

President Trump showed in his first term what happens when you unlock American science — breakthroughs happen fast.

Now, we’re going to do it again.

We know the power of U.S.…— Secretary Kennedy (@SecKennedy) June 20, 2025

SS likes to try and stir things up. Not even worth the time . 

And yet your idiotic premise is still grossly absurd.

I suggest a huddle with that other jester ol roge so you both can formulate an intelligent (most unlikely) talking point.